吉西他滨联合替吉奥二线治疗老年ⅢB期肺鳞癌疗效及安全性探讨.docVIP

吉西他滨联合替吉奥二线治疗老年ⅢB期肺鳞癌疗效及安全性探讨 　　[摘要] 目的 探讨吉西他滨联合替吉奥二线治疗老年ⅢB期肺鳞癌的疗效及安全性。方法 方便收集2010年3月―2015年5月在该院住院治疗的ⅢB期肺鳞癌患者110例，随机分为联合组和对照组，各55例。对照组单纯采用吉西他滨治疗，联合组采用吉西他滨联合替吉奥治疗，观察两组的临床疗效及安全性。结果 联合组的总有效率及疾病控制率分别为38.2%、49.1%，而对照组分别为18.2%、25.5%，差异有统计学意义（P0.05）；联合组中位PFS和OS分别为4.3、9.2个月，较对照组的3.8、8.0个月明显延长（P0.05）；白细胞降低、胃肠道反应率、口腔溃疡、疲乏发生率分别为89.1%、85.5%、29.1%、80.0%，较对照组的69.1%、45.5%、0.0%、41.8%明显增加。 结论 吉西他滨联合替吉奥治疗经一线治疗短期疗效差的老年ⅢB期肺鳞癌患者具有显著的效果，虽然不良反应率有一定升高，但患者均可耐受，安全性较好，值得借鉴。 　　[关键词] 吉西他滨；替吉奥；肺鳞癌 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-0742（2017）01（a）-0122-04 　　[Abstract] Objective To investigate the efficacy and safety of gemcitabine combined with S-1 second-line therapy for elderly patients with stage ⅢB lung squamous cell carcinoma. Methods Convenient selection from March，2010 to May 2015， 110 patients with stage ⅢB lung squamous cell carcinoma in our department were randomly divided into combination group and control group， there were 55 cases in each group. Control group were treated with gemcitabine and combination group were treated with gemcitabine combined with S-1，the clinical efficacy and safety of the two groups were observed. Results Combined group the total efficiency and disease control rate was 38.2%， 49.1%， while the control group were 18.2% and 25.5%， significant difference（P 0.05）； the combination group had a median PFS and OS were 4.3 months， 9.2 months， compared with the control group of 3.8 months， 8.0 months significantly prolonged（P 0.05）； reduced the number of white blood cells， gastrointestinal tract reaction rate， oral ulcer， fatigue occurrence rate of 89.1% and 85.5%， 29.1% and 80.0%， respectively， compared with that of the control group 69.1%， 45.5%， 0.0%， 41.8% increased significantly. Conclusion Gemcitabine Combined with S-1 therapy after first-line treatment of short-term curative effect difference of Age ⅢB stage lung squamous carcinoma patients has a significant effect， although the adverse reaction rate increased， but can be tolerated， safety is good， it